Results 51 to 60 of about 21,457 (213)
Neighborhood Socioeconomic Status and Short‐Term Functional Outcomes in Systemic Lupus Erythematosus
Arthritis Care &Research, Accepted Article.Objective Individuals with SLE can accumulate functional status (FS) impairment. We evaluated the association between neighborhood socioeconomic disadvantage, as measured by the area deprivation index (ADI), and FS in a national SLE sample. Methods Data were derived from RISE, a national electronic health record‐based registry.
Baljeet Rai +7 more
wiley +1 more source
Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review [PDF]
, 2014 BACKGROUND: Intravenous (IV) drug delivery is commonly used for its rapid administration and immediate drug effect. Most studies compare IV to subcutaneous (SC) delivery in terms of safety and efficacy, but little is known about what patients prefer.
Fallowfield, Lesley J +3 more
core +1 more source
Advanced Science, EarlyView.We studied how five common immunosuppressants behave when delivered directly to a transplant site instead of systemically. Using a vascularized implant for islet transplantation, we show that local delivery protects grafts, limits drug spread to the rest of the body, and produces distinct immune signatures.
Jocelyn Nikita Campa‐Carranza +19 more
wiley +1 more source
Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept
Case Reports in Rheumatology, 2014 Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial membrane inflammation and joint cartilage destruction. Abatacept is a biologic agent that blocks the costimulation signals, preventing antigen presentation and proliferation of ...
Fabio E. Ospina +4 more
doaj +1 more source
Arthritis Research & Therapy, 2019 Background Treatment persistence is an important consideration when selecting a therapy for chronic conditions such as rheumatoid arthritis (RA). We assessed the long-term persistence of abatacept or a tumor necrosis factor inhibitor (TNFi) following (1)
Denis Choquette +6 more
doaj +1 more source
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales [PDF]
, 2012 Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical ...
Andrew J. K. Ostor +9 more
core +2 more sources
Arthritis &Rheumatology, EarlyView.Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro +17 more
wiley +1 more source
Immunological Medicine, 2019 The aim of this study was to assess abatacept in rheumatoid arthritis (RA) patient. Patients (20 men, 89 women, aged 61.9 ± 10.4 y) who responded inadequately to conventional synthetic disease-modifying anti-rheumatic drug were treated with abatacept for
Noriyoshi Ogawa +14 more
doaj +1 more source
Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease [PDF]
The Korean Journal of Internal MedicineBackground/Aims To compare the effects of abatacept and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) on the progression and development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Kyung-Ann Lee +13 more
doaj +1 more source